|
| |
Visiongain Biotechnology and Pharmaceutical Conferences and Events
Contact |
Conferences
REGISTER online |
Reports | FAX ORDER FORM
 |
28th - 29th January 2010, BSG Conference Centre, London, UK
Advances in recombinant antibodies have impact on a range of therapy
areas, such as oncology, CNS, infectious and inflammatory diseases. With
an expert line-up of speakers, Visiongain's 3rd Annual Recombinant
Antibodies Conference is an ideal forum for industry and academia alike.
This 2-day event will explore novel applications of antibodies, recent
advances in antibody engineering and the latest clinical developments. |
|
 |
3rd - 4th March 2010, London, UK
Pharmaceutical and biopharmaceutical companies are under severe pressure
to improve product pipelines, accelerate time to market, and improve
margins on existing product, while maintaining strict adherence to
quality principles and regulatory requirements. It is imperative that
pharmaceutical and biotech companies address these business challenges
to stay competitive, increase revenue, enhance profit, and reduce the
risk of noncompliance. |
|
 |
2nd - 4th March 2010, Boston, USA
Biologics constitutes a major share of expenditure in the USA and
globally. It is one of the fastest growing sectors of the pharmaceutical
industry which corresponds to over 15% of the total pharmaceutical
market. There is a large and potentially lucrative demand for lower cost
biological drugs worldwide. With favourable regulatory developments, the
biosimilar sector should pick up significantly, however, forming an
important developing pharma market. |
|
 |
4th - 5th February 2010, BSG House, London, UK
Biobanking is changing rapidly. Biobanks are playing a vital role in the
today's research and development in the fields of drug discovery and
bioscience. The biobanking sector is expanding at a tremendous rate in
recent years and has also been facing many legal, financial, ethical,
scientific challenges. |
|
 |
25th - 26th January 2010, BSG Conference Centre, London, UK
Smoking cessation is among the most dynamic markets within the pharma,
biotech and healthcare sector, and expected to grow despite the current
economic times. According to visiongain's Smoking Cessation 2009-2024
report, the evolution of NRTs - including neuroreceptor modulators,
enzyme inhibitors and therapeutic vaccines - will push worldwide sales
of smoking cessation drugs to $1.5 billion by 2010, with majority of
revenues coming from the NRTs. |
|
 |
9th - 10th November 2009, BSG Conference Centre, London, UK
2009's financial turmoil has had a great impact on the pharmaceutical
and biotech industry. Pricing and reimbursement remains one of the most
notable issues in the globalized market. Pharmaceutical and biotech
companies are realigning their pricing and reimbursement strategies, and
taking cost containment measures to maintain the growth and
profitability. Adding to our successful series of P&R conferences in the
UK and USA, we are happy to unveil the much awaited Pharmaceutical
Pricing and Reimbursement Summit. |
|
 |
Attenuating the progression of hyperglycaemia, dyslipidaemia and
diabetic retinopathy
21st - 22nd January 2010, BSG House, London, UK
Set to double from $32 to $64bn over the next 15 years, the global
diabetes market is set for stellar growth as changing demographics and
new therapies begin entering the clinic. |
|
 |
10th - 11th February 2010, BSG House, London, UK
Drug delivery continues to be increasingly important sector in the
pharmaceutical industry and has undergone rapid growth in the last few
years. Drug delivery technologies are driving growth of pharmaceutical
companies and boosting their revenue by extending the product profitable
lifecycle through new formulations, combinations and repositioning. The
predominant focus of this conference will be in advancements being made
in the drug delivery technologies and understanding the regulatory and
legal issues faced by the them.
|
|
 |
7th - 8th December 2009, BSG House, London, UK
With more targets, more investment and more oppportunity than ever,
vaccine technology is among the most dynamic in biomedicine today.
Advances in reverse vaccinology, computer-aided biotechnology and
disposable technologies are revolutionising R&D for infectious disease,
paediatric and cancer therapies. Allied with new developments in
formualtion, informatics and process development, the market will see
growth of over 300% between 2009 and 2023.
|
|
 |
3rd - 4th December 2009, BSG House, London, UK
Dermatology is one of the most promising sectors within the global
pharmaceutical market. It has witnessed remarkable sales revenues of
over $18bn in 2007, and will expand significantly in the next 10 years.
Skin infections and disorders such as acne, psoriasis and dermatitis
remain major revenue generators for the pharmaceutical and biotech
companies. The dermatology market will regain 3.5% growth by 2010, with
the development of anti-psoriasis, acne and dermatitis products and
treatments (Source: visiongain). Our conference will focus on the
advances and innovations in novel drug delivery, therapeutic skin
treatments and anti-ageing products, primarily in the developing
countries.
|
|
 |
11th - 12th November 2009, BSG House, London, UK
Well planned, executed and managed stability studies are critical for
understanding data generated during clinical trials. Stability testing
is an expensive part of product development, but conducted efficiently,
it can save money in latter parts of the lifecycle. Visiongain's 3rd
Annual Stability Testing conference will examine developments in
technology for stability assessment. As part of this 2-day event,
leading authorities will assess the application and limitations of
various analytical and statistical methods, as well as study design.
Participants will be provided with a reliable evaluation of the
principles and techniques associated with the stability testing of
biologics and new pharmaceutical products. |
|
 |
30th - 31st March 2010, BSG House, London, UK
Regenerative medicine is set to revolutionise healthcare as stem cell,
tissue engineering, gene therapy and materials science come together to
transform patient treatment. Bringing you the latest in translational
applications from leading experts, don’t miss this exceptional showcase
of medical innovations in this fast-moving field. |
|
 |
16th - 18th November 2009, BSG House, London, UK
The recent surge in contract manufacturing landscape is influencing huge
challenges and opportunities in the global pharmaceutical market. The
highly competitive nature of the industry has been driving pharma and
biotech companies to set up off-shoring alliances with emerging markets
to minimise costs and maximise profits. |
|
 |
19th - 21st October 2009, BSG Conference Centre, London, UK
The biological drug market is one of the fastest growing sectors of the
pharmaceutical industry which corresponds to over 15% of the total
pharmaceutical market. However, due to the patent expiry of many drugs,
and increasing pressure from government, insurers and patient advocacy
groups to reduce expenditure a number of opportunities for biosimilars
have been created. |
|
 |
14th - 15th October 2009, BSG House, London
Breakthroughs in pain therapy have been rare in the past 50 years, but
there is increasing hope that advances in multiple areas of research
could lead to the introduction of much-needed novel and more effective
analgesics. Modern lifestyles and an aging population will lead the
global pain market, worth $35.6bn in 2009, to increase in value by over
50% to $55.2bn by 2023. |
|
| |
|
